Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05966584 · ClinicalTrials.gov registry record · Phase 2
A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT05966584: Clinical Trial Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT05966584 is a Phase 2 study that was terminated before completion, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05966584, a Phase 2 study, was terminated before completion, sponsored by Memorial Sloan Kettering Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
The researcher are doing this study to find out whether benralizumab is effective at preventing skin rashes caused by alpelisib in people who have metastatic breast cancer. Skin rash is a common side effect of alpelisib. Researchers think adding benralizumab to the standard-of-care hormone treatment and alpelisib may prevent the patient from getting a rash.
Interventions
- DRUG Benralizumab
- DRUG fulvestrant or AIs) and PI3K inhibition (alpelisib)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2023-07-06 |
| Est. Completion | 2024-08-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05966584
The ClinicalTrials.gov registry entry for NCT05966584 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Benralizumab is the first listed.
NCT05966584 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05966584 about?
NCT05966584 is a clinical study titled "A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer". The researcher are doing this study to find out whether benralizumab is effective at preventing skin rashes caused by alpelisib in people who have metastatic breast cancer. Skin rash is a common side effect of alpelisib. Researchers think adding benralizumab to the standard-of-care hormone treatment...
What is the current status of trial NCT05966584?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2023-07-06. Estimated completion is 2024-08-02.
What interventions are being tested in trial NCT05966584?
The interventions under investigation include: Benralizumab (DRUG), fulvestrant or AIs) and PI3K inhibition (alpelisib) (DRUG).
Who is sponsoring clinical trial NCT05966584?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.